Healthcare Review: Herbalife, Zynex, Sequenom, Cancer Genetics, Anacor Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Monday, 21 July 2014 14:01
U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and Gaza continue to garner investor focus. Israeli jets, tanks and artillery pounded Gaza again as the death toll from a two-week conflict topped 500 amid growing international calls for a ceasefire. Fighters from Hamas, which controls Gaza, have repeatedly tried to infiltrate Israel over the past week through hidden tunnels.

Shares of Herbalife ($HLF -6.2%) tank on a 2x surge in volume ahead of tomorrow's webcast at 10:00 am EDT by Bill Ackman's Pershing Square Capital Management. Mr. Ackman et al. will be presenting their findings from their investigation into the company's Nutrition Clubs.I nterested persons may access the presentation via

Zynex (OTCQB:ZYXI -13.8%) hires Brian Alleman as CFO replacing Anthony Scalese. He joins the firm from Alleman & Associates where he was Managing Director.

Sequenom (SQNM +3.6%) subsidiary Sequenom Laboratories plans to launch its VisibiliT laboratory-developed test (LDT) next month in ex. U.S. markets. The test utilizes chromosomal material from chromosomes 18 and 21 in combination with maternal age and fetal fraction to generate a personalized risk score for fetal trisomies such as Down syndrome and Edwards syndrome. The test is performed using a maternal blood sample and applies to a single gestation pregnancy considered to be at average risk.

Cancer Genetics (CGIX +3.8%) acquires privately-held Gentris Corp.,  a provider of genomic testing and pharmacogenomics services to biotech/pharma companies. Gentris will add $5M - 6M in top line revenue and contract backlog of over $18M. Financial terms are not disclosed.

Anacor Pharmaceuticals (NASDAQ:ANAC) enters into an exclusive agreement with Sandoz (NYSE:NVS) to commercialize Anacor's Kerydin (tavaborole) topical solution in the U.S. Sandoz's PharmaDerm division will be responsible for the sales and marketing of the recently-FDA cleared antifungal for the treatment of onychomycosis of the toenails.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus